DA Davidson lowered the firm’s price target on Nu Skin (NUS) to $7 from $11 and keeps a Neutral rating on the shares. The firm cites the company’s Q3 revenue miss and reduced guidance as the management noticed softness in the second half of FY24 and expects it to continue into 2025, the analyst tells investors in a research note. The top line decline could moderate in 2025, with sequential improvements throughout the year, but visibility into when the core business may stabilize remains low and cost initiatives appear insufficient to offset the unfavorable geographic mix, the firm added.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.